Abbott
Trade Abbott 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABT
Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
ABT Key Statistics
Stock Snapshot
With a market cap of 222.94B, Abbott(ABT) trades at $128.20. The stock has a price-to-earnings ratio of 16.07 and currently yields dividends of 1.8%.
On 2025-11-23, Abbott(ABT) stock moved within a range of $123.89 to $128.71. With shares now at $128.20, the stock is trading +3.5% above its intraday low and -0.4% below the session's peak.
Trading volume for Abbott(ABT) stock has reached 9.37M, versus its average volume of 7.07M.
The stock's 52-week range extends from a low of $110.86 to a high of $141.23.
The stock's 52-week range extends from a low of $110.86 to a high of $141.23.
ABT News
Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor m...
These healthcare stocks have long-term and profitable growth runways. If you are a new investor, healthcare stocks can provide numerous diversification benefit...
In a report released yesterday, Bruce Jackson from Benchmark Co. maintained a Buy rating on Abbott Laboratories, with a price target of $145.00. TipRanks Black...
Analyst ratings
70%
of 30 ratingsMore ABT News
Close Key Takeaways Abbott Laboratories has agreed to acquire Exact Sciences Corp. in a deal worth $21 billion, paying shareholders $105 per share. Exact Scie...
William Blair analyst Andrew Brackmann downgraded Exact Sciences (EXAS) to Market Perform from Outperform after the company announced an agreement to be acquire...
Exact Sciences (EXAS) shares soared roughly 20% on Thursday morning after Abbott (ABT) said it’s buying the molecular diagnostics firm in a deal that values it...
A healthcare giant covets the cancer screening leader's technology. Shares of Exact Sciences (EXAS +17.17%) climbed on Thursday after the medical diagnostics s...
Shares of Exact Sciences (EXAS), the cancer screening and treatment provider, surged by about 18% on Thursday morning after it agreed to merge with long-standin...
Abbott Laboratories agreed to acquire cancer-screening company Exact Sciences Corp., in a deal with a total equity value of about $21 billion. In the biggest h...
Exact Sciences sells Cologuard, the at-home test for colorectal cancer that allows some patients to skip colonoscopies. Abbott is getting into cancer testing w...
